134 related articles for article (PubMed ID: 3550604)
1. [Structure and activity of anthracyclines].
Lavelle F
Pathol Biol (Paris); 1987 Jan; 35(1):11-9. PubMed ID: 3550604
[TBL] [Abstract][Full Text] [Related]
2. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
[TBL] [Abstract][Full Text] [Related]
3. Anti-cancer activity of anthracycline antibiotics and DNA condensation.
Cera C; Palumbo M
Anticancer Drug Des; 1990 Aug; 5(3):265-71. PubMed ID: 2400539
[TBL] [Abstract][Full Text] [Related]
4. Enzymatic and chemical footprinting of anthracycline antitumor antibiotics and related saccharide side chains.
Shelton CJ; Harding MM; Prakash AS
Biochemistry; 1996 Jun; 35(24):7974-82. PubMed ID: 8672501
[TBL] [Abstract][Full Text] [Related]
5. Change of the sequence specificity of daunorubicin-stimulated topoisomerase II DNA cleavage by epimerization of the amino group of the sugar moiety.
Capranico G; Butelli E; Zunino F
Cancer Res; 1995 Jan; 55(2):312-7. PubMed ID: 7812964
[TBL] [Abstract][Full Text] [Related]
6. Human heart cytosolic reductases and anthracycline cardiotoxicity.
Mordente A; Meucci E; Martorana GE; Giardina B; Minotti G
IUBMB Life; 2001 Jul; 52(1-2):83-8. PubMed ID: 11795600
[TBL] [Abstract][Full Text] [Related]
7. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity.
Minotti G; Cavaliere AF; Mordente A; Rossi M; Schiavello R; Zamparelli R; Possati G
J Clin Invest; 1995 Apr; 95(4):1595-605. PubMed ID: 7706466
[TBL] [Abstract][Full Text] [Related]
8. Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation.
Animati F; Arcamone F; Bigioni M; Capranico G; Caserini C; De Cesare M; Lombardi P; Pratesi G; Salvatore C; Supino R; Zunino F
Mol Pharmacol; 1996 Sep; 50(3):603-9. PubMed ID: 8794900
[TBL] [Abstract][Full Text] [Related]
9. Association of anthracyclines and synthetic hexanucleotides. Structural factors influencing sequence specificity.
Rizzo V; Battistini C; Vigevani A; Sacchi N; Razzano G; Arcamone F; Garbesi A; Colonna FP; Capobianco M; Tondelli L
J Mol Recognit; 1989 Nov; 2(3):132-41. PubMed ID: 2636902
[TBL] [Abstract][Full Text] [Related]
10. Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin.
Taatjes DJ; Gaudiano G; Resing K; Koch TH
J Med Chem; 1997 Apr; 40(8):1276-86. PubMed ID: 9111302
[TBL] [Abstract][Full Text] [Related]
11. Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells.
Bogush T; Robert J
Anticancer Res; 1996; 16(1):365-8. PubMed ID: 8615637
[TBL] [Abstract][Full Text] [Related]
12. Studies of anthracycline--DNA complexes by circular dichroism.
Rizzo V; Penco S; Menozzi M; Geroni C; Vigevani A; Arcamone F
Anticancer Drug Des; 1988 Aug; 3(2):103-15. PubMed ID: 3165639
[TBL] [Abstract][Full Text] [Related]
13. Sequence specificity in the binding of anti-tumour anthracyclines to DNA: a success of theory.
Pullman B
Anticancer Drug Des; 1991 May; 6(2):95-105. PubMed ID: 2039585
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of RNA synthesis in vitro and cell growth by anthracycline antibiotics.
Studzian K; Wasowska M; Piestrzeniewicz MK; Wilmańska D; Szmigiero L; Oszczapowicz I; Gniazdowski M
Neoplasma; 2001; 48(5):412-8. PubMed ID: 11845988
[TBL] [Abstract][Full Text] [Related]
15. [Genotoxic and mutagenic activity of antineoplastic anthracyclines and their aglycones: study in two test-systems].
Vasil'eva SV; Makhova EV; Efremenkova OV; Bartoshevich IuE
Genetika; 1996 Feb; 32(2):233-9. PubMed ID: 8713623
[TBL] [Abstract][Full Text] [Related]
16. Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit.
Jaenke RS; Deprez-DeCampeneere D; Trouet A
Cancer Res; 1980 Oct; 40(10):3530-6. PubMed ID: 6934026
[TBL] [Abstract][Full Text] [Related]
17. 4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.
Menna P; Salvatorelli E; Minotti G
Chem Res Toxicol; 2009 Jun; 22(6):978-83. PubMed ID: 19397277
[TBL] [Abstract][Full Text] [Related]
18. An introduction to the metabolic determinants of anthracycline cardiotoxicity.
Menna P; Recalcati S; Cairo G; Minotti G
Cardiovasc Toxicol; 2007; 7(2):80-5. PubMed ID: 17652809
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design of a new bisintercalating anthracycline antibiotic.
Chaires JB; Leng F; Przewloka T; Fokt I; Ling YH; Perez-Soler R; Priebe W
J Med Chem; 1997 Jan; 40(3):261-6. PubMed ID: 9022792
[TBL] [Abstract][Full Text] [Related]
20. Influence of the structure of new anthracycline antibiotics on their biological properties.
Wasowska M; Oszczapowicz I; Wietrzyk J; Opolski A; Madej J; Dzimira S; Oszczapowicz J
Anticancer Res; 2005; 25(3B):2043-8. PubMed ID: 16158943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
